Chronic administration of atypical antipsychotics improves behavioral and synaptic defects of STOP null mice

Psychopharmacology

Volumn 208, Issue 1, 2010, Pages 131-141

  Delotterie, David ^a   Ruiz, Geoffrey ^a,b,c   Brocard, Jacques ^b,c   Schweitzer, Annie ^b,c   Roucard, Corinne ^a   Roche, Yann ^a   Suaud Chagny, Marie Françoise ^d   Bressand, Karine ^a   Andrieux, Annie ^b,c  

^a SynapCell   (France)

^b INSERM   (France)

^c CEA GRENOBLE   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

Antipsychotics; Cognitive defects; Schizophrenia; Social investigation; STOP null mice

Indexed keywords

CLOZAPINE; CYTOSKELETON PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; MICROTUBULE ASSOCIATED PROTEIN STOP; PLACEBO; RISPERIDONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR CHANGE; BEHAVIOR DISORDER; CHRONIC DRUG ADMINISTRATION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFECT; FORCED SWIMMING TEST; GENE DELETION; HIPPOCAMPUS; LONG TERM POTENTIATION; MALE; MAZE TEST; MOUSE; NEGATIVE SYNDROME; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; SOCIAL BEHAVIOR;

EID: 72649085418     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-009-1712-3     Document Type: Article

References (50)

1. A Andrieux PA Salin M Vernet P Kujala J Baratier S Gory-Fauré C Bosc H Pointu D Proietto A Schweitzer E Denarier J Klumperman D Job 2002 The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders Genes Dev 16 2350 2364 10.1101/gad.223302 1:CAS:528:DC%2BD38XnsFelsrc%3D 12231625 (Pubitemid 35034405)
2. TR Barnes DA Curson PF Liddle M Patel 1989 The nature and prevalence of depression in chronic schizophrenic in-patients Br J Psychiatry 154 486 491 10.1192/bjp.154.4.486 1:STN:280:DyaK3c%2FnsVyrug%3D%3D 2574068
3. M Begou P Brun JB Bertrand D Job A Schweitzer T D'Amato M Saoud A Andrieux MF Suaud-Chagny 2007 Post-pubertal emergence of alterations in locomotor activity in stop null mice Synapse 61 689 697 10.1002/syn.20409 1:CAS:528:DC%2BD2sXosVOis7w%3D 17559095 (Pubitemid 47122740)
4. M Bégou J Volle JB Bertrand P Brun D Job A Schweitzer M Saoud T D'Amato A Andrieux MF Suaud-Chagny 2008 The stop null mice model for schizophrenia displays cognitive and social deficits partly alleviated by neuroleptics Neuroscience 157 29 39 10.1016/j.neuroscience.2008.07.080 18804150
5. DH Blackwood BJ Pickard PA Thomson KL Evans DJ Porteous WJ Muir 2007 Are some genetic risk factors common to schizophrenia, bipolar disorder and depression? Evidence from DISC1, GRIK4 and NRG1 Neurotox Res 11 73 83 10.1007/BF03033484 1:CAS:528:DC%2BD2sXktVeqt74%3D 17449450
6. C Bouvrais-Veret S Weiss A Andrieux A Schweitzer JM McIntosh D Job B Giros MP Martres 2007 Sustained increase of alpha7 nicotinic receptors and choline-induced improvement of learning deficit in STOP knock-out mice Neuropharmacology 52 1691 1700 10.1016/j.neuropharm.2007.03.015 1:CAS:528:DC%2BD2sXmtVegs7s%3D 17512560 (Pubitemid 46850753)
7. E Brenner U Sonnewald A Schweitzer A Andrieux A Nehlig 2007 Hypoglutamatergic activity in the STOP knockout mouse: a potential model for chronic untreated schizophrenia J Neurosci Res 85 3487 3493 10.1002/jnr.21200 1:CAS:528:DC%2BD1cXjtFCltrs%3D 17304567 (Pubitemid 350058536)
8. P Brun M Bégou A Andrieux L Mouly-Badina M Clerget A Schweitzer H Scarna B Renaud D Job MF Suaud-Chagny 2005 Dopaminergic transmission in STOP null mice J Neurochem 94 63 73 10.1111/j.1471-4159.2005.03166.x 1:CAS:528:DC%2BD2MXlvFCksLg%3D 15953350 (Pubitemid 40911393)
9. LM Camargo Q Wang NJ Brandon 2008 What can we learn from the disrupted in schizophrenia 1 interactome: lessons for target identification and disease biology? Novartis Found Symp 289 208 216 10.1002/9780470751251.ch17 1:CAS:528:DC%2BD1cXps1Kjurg%3D 18497105 discussion 216-21, 238-40
10. S Chiba R Hashimoto S Hattori M Yohda B Lipska DR Weinberger H Kunugi 2006 Effect of antipsychotic drugs on DISC1 and dysbindin expression in mouse frontal cortex and hippocampus J Neural Transm 113 1337 1346 10.1007/s00702-005-0414-1 1:CAS:528:DC%2BD28Xosleqsbk%3D 16463116 (Pubitemid 44291026)
11. SJ Clapcote TV Lipina JK Millar S Mackie S Christie F Ogawa JP Lerch K Trimble M Uchiyama Y Sakuraba H Kaneda T Shiroishi MD Houslay RM Henkelman JG Sled Y Gondo DJ Porteous JC Roder 2007 Behavioral phenotypes of Disc1 missense mutations in mice Neuron 54 387 402 10.1016/j.neuron.2007.04.015 1:CAS:528:DC%2BD2sXmtVOjsrc%3D 17481393 (Pubitemid 46671409)
12. JT Coyle G Tsai 2004 NMDA receptor function, neuroplasticity, and the pathophysiology of schizophrenia Int Rev Neurobiol 59 491 515 10.1016/S0074-7742(04)59019-0 1:CAS:528:DC%2BD2cXktVertbc%3D 15006500 (Pubitemid 39752426)
13. E Denarier M Aguezzoul C Jolly C Vourc'h A Roure A Andrieux C Bosc D Job 1998 Genomic structure and chromosomal mapping of the mouse STOP gene (Mtap6) Biochem Biophys Res Commun 243 791 796 10.1006/bbrc.1998.8179 1:CAS:528:DyaK1cXhsFCgt7c%3D 9501006 (Pubitemid 28414159)
14. X Duan JH Chang S Ge RL Faulkner JY Kim Y Kitabatake XB Liu CH Yang JD Jordan DK Ma CY Liu S Ganesan HJ Cheng GL Ming B Lu H Song 2007 Disrupted-in-schizophrenia 1 regulates integration of newly generated neurons in the adult brain Cell 130 1146 1158 10.1016/j.cell.2007.07.010 1:CAS:528:DC%2BD2sXhtFKnurjI 17825401 (Pubitemid 47422304)
15. GE Duncan S Zorn JA Lieberman 1999 Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia Mol Psychiatry 4 418 428 10.1038/sj.mp.4000581 1:CAS:528:DC%2BD3cXlvVWltb8%3D 10523814
16. SL Eastwood L Lyon L George A Andrieux D Job PJ Harrison 2007 Altered expression of synaptic protein mRNAs in STOP (MAP6) mutant mice J Psychopharmacol 21 635 644 10.1177/0269881106068825 1:CAS:528:DC%2BD2sXhtFalt77K 17050659 (Pubitemid 47472734)
17. BA Ellenbroek AR Cools 1990 Animal models with construct validity for schizophrenia Behav Pharmacol 1 469 490 10.1097/00008877-199000160-00001 11175433
18. L Ereshefsky TK Tran-Johnson MD Watanabe 1990 Pathophysiologic basis for schizophrenia and the efficacy of antipsychotics Clin Pharm 9 682 707 1:STN:280:DyaK3M%2FjtVChsw%3D%3D 1977544
19. RL Fradley GF O'Meara RJ Newman A Andrieux D Job DS Reynolds 2005 STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating Behav Brain Res 163 257 264 10.1016/j.bbr.2005.05.012 1:CAS:528: DC%2BD2MXns1Wjsbs%3D 16046005 (Pubitemid 41138060)
20. WG Frankle J Lerma M Laruelle 2003 The synaptic hypothesis of schizophrenia Neuron 39 205 216 10.1016/S0896-6273(03)00423-9 1:CAS:528:DC%2BD3sXlvFyrs7g%3D 12873379 (Pubitemid 36897544)
21. T Hikida H Jaaro-Peled S Seshadri K Oishi C Hookway S Kong D Wu R Xue M Andrade S Tankou S Mori M Gallagher K Ishizuka M Pletnikov S Kida A Sawa 2007 Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans Proc Natl Acad Sci USA 104 14501 14506 10.1073/pnas.0704774104 1:CAS:528:DC%2BD2sXhtVGmtr3O 17675407 (Pubitemid 350003290)
22. K Ishizuka M Paek A Kamiya A Sawa 2006 A review of disrupted-in- schizophrenia-1 (DISC1): neurodevelopment, cognition, and mental conditions Biol Psychiatry 59 1189 1197 10.1016/j.biopsych.2006.03.065 1:CAS:528: DC%2BD28XmtVOit7g%3D 16797264 (Pubitemid 43912556)
23. S Leucht C Corves D Arbter RR Engel C Li JM Davis 2009 Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis Lancet 373 31 41 10.1016/S0140-6736(08)61764-X 1:CAS:528:DC%2BD1MXht1Wqsw%3D%3D 19058842
24. CM Lewis DF Levinson LH Wise LE DeLisi RE Straub I Hovatta NM Williams SG Schwab AE Pulver SV Faraone LM Brzustowicz CA Kaufmann DL Garver HM Gurling E Lindholm H Coon HW Moises W Byerley SH Shaw A Mesen R Sherrington FA O'Neill D Walsh KS Kendler J Ekelund T Paunio J Lonnqvist L Peltonen MC O'Donovan MJ Owen DB Wildenauer W Maier G Nestadt JL Blouin SE Antonarakis BJ Mowry JM Silverman RR Crowe CR Cloninger MT Tsuang D Malaspina JM Harkavy-Friedman DM Svrakic AS Bassett J Holcomb G Kalsi A McQuillin J Brynjolfson T Sigmundsson H Petursson E Jazin T Zoega T Helgason 2003 Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: schizophrenia Am J Hum Genet 73 34 48 10.1086/376549 1:CAS:528:DC%2BD3sXlsVOitL8%3D 12802786 (Pubitemid 36793778)
25. S Mackie JK Millar DJ Porteous 2007 Role of DISC1 in neural development and schizophrenia Curr Opin Neurobiol 17 95 102 10.1016/j.conb.2007.01.007 1:CAS:528:DC%2BD2sXhvVOqur4%3D 17258902 (Pubitemid 46227982)
26. D Martins-de-Souza WF Gattaz A Schmitt C Rewerts G Maccarrone E Dias-Neto CW Turck 2009 Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia Eur Arch Psychiatry Clin Neurosci 259 151 163 10.1007/s00406-008-0847-2 19165527
27. S Matsuzaki M Tohyama 2007 Molecular mechanism of schizophrenia with reference to disrupted-in-schizophrenia 1 (DISC1) Neurochem Int 51 165 172 10.1016/j.neuint.2007.06.018 1:CAS:528:DC%2BD2sXosFOhurg%3D 17664024 (Pubitemid 47176713)
28. HY Meltzer 2004 What's atypical about atypical antipsychotic drugs? Curr Opin Pharmacol 4 53 57 10.1016/j.coph.2003.09.010 1:CAS:528: DC%2BD2cXpsVGjtA%3D%3D 15018839 (Pubitemid 38145838)
29. KA Miczek H de Wit 2008 Challenges for translational psychopharmacology research-some basic principles Psychopharmacology (Berl) 199 291 301 10.1007/s00213-008-1198-4 1:CAS:528:DC%2BD1cXotVyrsbY%3D
30. MJ Millan A Dekeyne M Papp CD La Rochelle C MacSweeny JL Peglion M Brocco 2001 S33005, a novel ligand at both serotonin and norepinephrine transporters: II. Behavioral profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine J Pharmacol Exp Ther 298 581 591 1:CAS:528:DC%2BD3MXlsVKqsLg%3D 11454919
31. K Mirnics FA Middleton DA Lewis P Levitt 2001 Analysis of complex brain disorders with gene expression microarrays: schizophrenia as a disease of the synapse Trends Neurosci 24 479 486 10.1016/S0166-2236(00)01862-2 1:CAS:528:DC%2BD3MXltlymsLg%3D 11476888 (Pubitemid 32695360)
32. KT Mueser SR McGurk 2004 Schizophrenia Lancet 363 2063 2072 10.1016/S0140-6736(04)16458-1 15207959 (Pubitemid 38781110)
33. LB Nicolas Y Kolb EP Prinssen 2006 A combined marble burying-locomotor activity test in mice: a practical screening test with sensitivity to different classes of anxiolytics and antidepressants Eur J Pharmacol 547 106 115 10.1016/j.ejphar.2006.07.015 1:CAS:528:DC%2BD28Xps1OmtLo%3D 16934246 (Pubitemid 44373902)
34. Y Noda K Yamada H Furukawa T Nabeshima 1995 Enhancement of immobility in a forced swimming test by subacute or repeated treatment with phencyclidine: a new model of schizophrenia Br J Pharmacol 116 2531 2537 1:CAS:528: DyaK2MXptlertLY%3D 8581295
35. Y Noda T Mamiya H Furukawa T Nabeshima 1997 Effects of antidepressants on phencyclidine-induced enhancement of immobility in a forced swimming test in mice Eur J Pharmacol 324 135 140 10.1016/S0014-2999(97)00067-8 1:CAS:528:DyaK2sXisVemt78%3D 9145763 (Pubitemid 27174597)
36. MJ Owen N Craddock MC O'Donovan 2005 Schizophrenia: genes at last? Trends Genet 21 518 525 10.1016/j.tig.2005.06.011 1:CAS:528:DC%2BD2MXns1Squ7o%3D 16009449 (Pubitemid 41132587)
37. MJ Owen MC O'Donovan PJ Harrison 2005 Schizophrenia: a genetic disorder of the synapse? BMJ 330 158 159 10.1136/bmj.330.7484.158 15661762
38. ST Patil L Zhang F Martenyi SL Lowe KA Jackson BV Andreev AS Avedisova LM Bardenstein IY Gurovich MA Morozova SN Mosolov NG Neznanov AM Reznik AB Smulevich VA Tochilov BG Johnson JA Monn DD Schoepp 2007 Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial Nat Med 13 1102 1107 10.1038/nm1632 1:CAS:528:DC%2BD2sXhtVSgtrvF 17767166 (Pubitemid 47517511)
39. J Peuskens C Demily F Thibaut 2005 Treatment of cognitive dysfunction in schizophrenia Clin Ther 27 S25 S37 10.1016/j.clinthera.2005.07.015 1:CAS:528:DC%2BD2MXhtVWqsLnI 16198199 (Pubitemid 41356721)
40. RD Porsolt A Bertin M Jalfre 1977 Behavioral despair in mice: a primary screening test for antidepressants Arch Int Pharmacodyn Ther 229 327 336 1:CAS:528:DyaE1cXktlKgsbs%3D 596982
41. RD Porsolt G Anton N Blavet M Jalfre 1978 Behavioural despair in rats: a new model sensitive to antidepressant treatments Eur J Pharmacol 47 379 391 10.1016/0014-2999(78)90118-8 1:CAS:528:DyaE1cXhvVagsr0%3D 204499
42. KJ Powell SE Hori R Leslie A Andrieux H Schellinck M Thorne GS Robertson 2007 Cognitive impairments in the STOP null mouse model of schizophrenia Behav Neurosci 121 826 835 10.1037/0735-7044.121.5.826 17907815 (Pubitemid 350064351)
43. M Sakaguchi M Koseki M Wakamatsu E Matsumura 2006 Effects of systemic administration of beta-casomorphin-5 on learning and memory in mice Eur J Pharmacol 530 81 87 10.1016/j.ejphar.2005.11.014 1:CAS:528: DC%2BD28XhsFeqsA%3D%3D 16360145 (Pubitemid 43037127)
44. MJ Sergi Y Rassovsky C Widmark C Reist S Erhart DL Braff SR Marder MF Green 2007 Social cognition in schizophrenia: relationships with neurocognition and negative symptoms Schizophr Res 90 316 324 10.1016/j.schres.2006.09.028 17141477 (Pubitemid 46177558)
45. H Shimizu Y Iwayama K Yamada T Toyota Y Minabe K Nakamura M Nakajima E Hattori N Mori N Osumi T Yoshikawa 2006 Genetic and expression analyses of the STOP (MAP6) gene in schizophrenia Schizophr Res 84 244 252 10.1016/j.schres. 2006.03.017 16624526
46. T Shinoda S Taya D Tsuboi T Hikita R Matsuzawa S Kuroda A Iwamatsu K Kaibuchi 2007 DISC1 regulates neurotrophin-induced axon elongation via interaction with Grb2 J Neurosci 27 4 14 10.1523/JNEUROSCI.3825-06.2007 1:CAS:528:DC%2BD2sXmvFCluw%3D%3D 17202467 (Pubitemid 46089954)
47. K Talbot DS Cho WY Ong MA Benson LY Han HA Kazi J Kamins CG Hahn DJ Blake SE Arnold 2006 Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin Hum Mol Genet 15 3041 3054 10.1093/hmg/ddl246 1:CAS:528: DC%2BD28XhtVOgt7%2FM 16980328 (Pubitemid 44530708)
48. S Taya T Shinoda D Tsuboi J Asaki K Nagai T Hikita S Kuroda K Kuroda M Shimizu S Hirotsune A Iwamatsu K Kaibuchi 2007 DISC1 regulates the transport of the NUDEL/LIS1/14-3-3epsilon complex through kinesin-1 J Neurosci 27 15 26 10.1523/JNEUROSCI.3826-06.2006 1:CAS:528:DC%2BD2sXmvFCksg%3D%3D 17202468 (Pubitemid 46089955)
49. J Volavka P Czobor B Sheitman JP Lindenmayer L Citrome JP McEvoy TB Cooper M Chakos JA Lieberman 2002 Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder Am J Psychiatry 159 255 262 10.1176/appi.ajp.159.2.255 11823268 (Pubitemid 34126903)
50. R Young S Batkai M Dukat RA Glennon 2006 TDIQ (5, 6, 7, 8-tetrahydro-1, 3-dioxolo[4, 5-g]isoquinoline) exhibits anxiolytic-like activity in a marble-burying assay in mice Pharmacol Biochem Behav 84 62 73 10.1016/j.pbb.2006.04.006 1:CAS:528:DC%2BD28Xmslyrsr4%3D 16750844